Back to results
US 8,815,233 B2Granted
Method for treating pervasive development disorders
AssigneeCuremark, LLC
InventorJoan M. Fallon
Life of this patent
Estimating the term…
Abstract
A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.
Claims20
A method of treating a pervasive development disorder (PDD), comprising:
- administering a pharmaceutical composition comprising digestive enzymes to an individual having a PDD and a subnormal level of fecal chymotrypsin, wherein the digestive enzymes comprise amylase, protease and lipase, and wherein one or more symptoms of the PDD are ameliorated.
Dependencies are inferred from the claim text.